MAIA Biotechnology, Inc. reported positive preliminary efficacy data from its ongoing Phase 2 clinical trial for its drug candidate THIO in combination with Regeneron's anti-PD-1 cemiplimab for advanced Non-Small Cell Lung Cancer. They also announced positive results from an investigational new drug-enabling study for their second-generation telomere-targeting agents.